Literature DB >> 7684572

Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.

K F Rabe1, H Tenor, G Dent, C Schudt, S Liebig, H Magnussen.   

Abstract

The effects of the nonselective phosphodiesterase (PDE)-inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the selective PDE inhibitors SKF 94120 (type III), rolipram (type IV), zardaverine (type III/IV), and zaprinast (type V) on inherent tone in human airways were investigated. Substantial relaxation was achieved by IBMX [concentration eliciting 50% of maximum response (EC50): 2.9 microM, n = 14] and SKF 94120 (EC50: 1.4 microM, n = 15); rolipram and zaprinast were almost ineffective. Zardaverine (EC50: 0.31 microM, n = 8), and the combination of SKF 94120 and rolipram (1 microM; EC50: 0.41 microM) were effective relaxants. Biochemical studies revealed the presence of PDE isozymes I, III, IV, and V in the cytosolic and particulate phase of airway homogenates, whereas PDE II was present only in the cytosol. Partial inhibition of total PDE adenosine 3',5'-cyclic monophosphate-hydrolyzing activity was achieved with rolipram and a selective type III inhibitor, whereas there was almost complete inhibition of total PDE activity with either zardaverine or the combination of type III and IV inhibitors. We conclude that all five PDE isozyme families are present in crude preparations of human peripheral airways. Inherent tone in this tissue is most effectively relaxed through selective type III/IV PDE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684572     DOI: 10.1152/ajplung.1993.264.5.L458

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  23 in total

1.  Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.

Authors:  J Cortijo; V Villagrasa; C Navarrete; C Sanz; L Berto; A Michel; P A Bonnet; E J Morcillo
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 2.  Airway smooth muscle relaxation.

Authors:  A J Knox; A E Tattersfield
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

3.  The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways.

Authors:  D T Schmidt; N Watson; G Dent; E Rühlmann; D Branscheid; H Magnussen; K F Rabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility.

Authors:  R Venkatasamy; D Spina
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 5.  cAMP regulation of airway smooth muscle function.

Authors:  Charlotte K Billington; Oluwaseun O Ojo; Raymond B Penn; Satoru Ito
Journal:  Pulm Pharmacol Ther       Date:  2012-05-24       Impact factor: 3.410

6.  Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle.

Authors:  E Naline; Y Qian; C Advenier; D Raeburn; J A Karlsson
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 7.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

8.  Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.

Authors:  Rodney D Britt; Michael A Thompson; Ine Kuipers; Alecia Stewart; Elizabeth R Vogel; James Thu; Richard J Martin; Christina M Pabelick; Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-07       Impact factor: 5.464

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.